Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan 430071, P.R. China.
Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan 430060, P.R. China.
Theranostics. 2024 Jun 17;14(10):3859-3899. doi: 10.7150/thno.96516. eCollection 2024.
Osteoporosis is a systemic skeletal disease caused by an imbalance between bone resorption and formation. Current treatments primarily involve systemic medication and hormone therapy. However, these systemic treatments lack directionality and are often ineffective for locally severe osteoporosis, with the potential for complex adverse reactions. Consequently, treatment strategies using bioactive materials or external interventions have emerged as the most promising approaches. This review proposes twelve microenvironmental treatment targets for osteoporosis-related pathological changes, including local accumulation of inflammatory factors and reactive oxygen species (ROS), imbalance of mitochondrial dynamics, insulin resistance, disruption of bone cell autophagy, imbalance of bone cell apoptosis, changes in neural secretions, aging of bone cells, increased local bone tissue vascular destruction, and decreased regeneration. Additionally, this review examines the current research status of effective or potential biophysical and biochemical stimuli based on these microenvironmental treatment targets and summarizes the advantages and optimal parameters of different bioengineering stimuli to support preclinical and clinical research on osteoporosis treatment and bone regeneration. Finally, the review addresses ongoing challenges and future research prospects.
骨质疏松症是一种由骨吸收和形成失衡引起的全身性骨骼疾病。目前的治疗主要包括系统药物治疗和激素治疗。然而,这些全身治疗缺乏针对性,对于局部严重的骨质疏松症往往效果不佳,且可能会产生复杂的不良反应。因此,使用生物活性材料或外部干预的治疗策略已成为最有前途的方法。本综述提出了与骨质疏松相关病理变化的 12 个微环境治疗靶点,包括局部炎症因子和活性氧(ROS)的积累、线粒体动力学失衡、胰岛素抵抗、破骨细胞自噬障碍、成骨细胞凋亡失衡、神经分泌变化、骨细胞衰老、局部骨组织血管破坏增加以及再生减少。此外,本综述还基于这些微环境治疗靶点,研究了基于这些微环境治疗靶点的有效或潜在生物物理和生化刺激的最新研究现状,并总结了不同生物工程刺激的优缺点和最佳参数,以支持骨质疏松症治疗和骨再生的临床前和临床研究。最后,本文讨论了当前的挑战和未来的研究前景。
Front Endocrinol (Lausanne). 2024
Macromol Rapid Commun. 2025-1
Maturitas. 2013-4-4
Front Endocrinol (Lausanne). 2022
Curr Osteoporos Rep. 2016-10
Curr Osteoporos Rep. 2016-6
Biomaterials. 2023-5
Crit Rev Clin Lab Sci. 2024-9
Int J Nanomedicine. 2024
Bioact Mater. 2023-12-27